Journals / Trakya University Journal of Natural Sciences / 2026 / Volume: 27 Issue: 1

Chemical inhibition of the heat shock response downregulates ERCC1 gene expression and shifts carboplatin-induced necrosis to apoptosis in TNBC cells

Beyza Reisoğlu(ONDOKUZ MAYIS UNIVERSITY, MOLECULAR MEDICINE (DR))
M. Alper Arslan(ONDOKUZ MAYIS UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES, MEDICAL DEPARTMENT OF BIOLOGY)
Pages
—
Publication Date
2026-07-09
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Given the aggressive nature of TNBC and its limited treatment options, our results suggest that KNK437 may offer therapeutic advantages when combined with carboplatin, particularly in contexts where carboplatin-induced necrosis contributes to inflammationrelated complications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Triple-negative breast cancer (TNBC) is an aggressive cancer type associated with poor prognosis and limited therapeutic options.
📊
Key Findings & Data:ERCC1 is a critical component of the nucleotide excision repair system, responsible for repairing DNA damaged by platinum-based agents like carboplatin.
💡
Conclusion & Impact:Given the aggressive nature of TNBC and its limited treatment options, our results suggest that KNK437 may offer therapeutic advantages when combined with carboplatin, particularly in contexts where carboplatin-induced necrosis contributes to inflammationrelated complications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:KNK437 · carboplatin · ERCC1

Abstract

Background: Triple-negative breast cancer (TNBC) is an aggressive cancer type associated with poor prognosis and limited therapeutic options. Due to the absence of targetable receptors, conventional chemotherapy remains the primary treatment approach. ERCC1 is a critical component of the nucleotide excision repair system, responsible for repairing DNA damaged by platinum-based agents like carboplatin. Heat shock response (HSR) is a fundamental, stressinduced defense mechanism that supports cancer cell survival. Aims: This study aims to investigate the effects of HSR inhibition by KNK437 on ERCC1 gene expression and carboplatin sensitivity in the TNBC cell line MDA-MB-231. Methods: The IC50 values of carboplatin and KNK437 were determined using WST-8 cytotoxicity assay. ERCC1 gene expression levels were quantified by real-time quantitative polymerase chain reaction. Apoptotic and necrotic cell death induced by carboplatin and KNK437 was assessed by flow cytometry using FITC-Annexin V assay. Results: The IC50 values of carboplatin and KNK437 were 247.5 µM and 89.74 µM, respectively. Carboplatin or KNK437 monotherapy significantly decreased ERCC1 expression by 42.8% and 49.5%, respectively, while their combined application caused a 54.9% reduction. Furthermore, co-treatment markedly increased total cell death by 34.1% compared to carboplatin alone. Interestingly, necrosis induced by carboplatin shifted toward apoptosis upon co-treatment with KNK437, as confirmed by light microscopy and flow cytometry. Conclusion: HSR inhibition by KNK437 enhances carboplatin sensitivity in TNBC cells and downregulates ERCC1 gene expression. Given the aggressive nature of TNBC and its limited treatment options, our results suggest that KNK437 may offer therapeutic advantages when combined with carboplatin, particularly in contexts where carboplatin-induced necrosis contributes to inflammationrelated complications.

🔖

Cite This Article

Reisoğlu, B., Arslan, M. A. (2026). Chemical inhibition of the heat shock response downregulates ERCC1 gene expression and shifts carboplatin-induced necrosis to apoptosis in TNBC cells. Trakya University Journal of Natural Sciences, Volume: 27 Issue: 1. https://doi.org/10.23902/trkjnat.202573

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (34)

  1. Akkız, H., Şimşek, H., Balcı, D., Ülger, Y., Onan, E., Akçaer, N., & Delik, A. (2025). Inflammation and cancer: Molecular mechanisms and clinical consequences. Frontiers in Oncology, 15, 1564572. https://doi.org/10.3389/fonc.2025.1564572
  2. Aranda-Anzaldo, A., Dent, M. A. R., Segura-Anaya, E., & MartinezGomez, A. (2024). Protein folding, cellular stress and cancer. Progress in Biophysics and Molecular Biology, 191, 40–57. https://doi.org/10.1016/j.pbiomolbio.2024.07.001
  3. Balvan, J., Krizova, A., Gumulec, J., Raudenska, M., Sladek, Z., Sedlackova, M., Babula, P., Sztalmachova, M., Kizek, R., Chmelik, R., & Masarik, M. (2015). Multimodal holographic microscopy: Distinction between apoptosis and oncosis. PLOS ONE, 10(3), e0121674. https://doi.org/10.1371/journal.pone.0121674
  4. Barrio, S., Gallardo, M., Arenas, A., Ayala, R., Rapado, I., Rueda, D., JimenezUbieto, A., Albizua, E., Burgaleta, C., Gilsanz, F., & Martinez-Lopez, J. (2013). Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. British Journal of Haematology, 161(5), 667–676. https://doi.org/10.1111/bjh.12308
  5. Bian, L., Yu, P., Wen, J., Li, N., Huang, W., Xie, X., & Ye, F. (2021). Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials. NPJ Breast Cancer, 7(1), 157. https://doi.org/10.1038/s41523-021-00367-w
  6. Bou Zerdan, M., Ghorayeb, T., Saliba, F., Allam, S., Bou Zerdan, M., Yaghi, M., Bilani, N., Jaafar, R., & Nahleh, Z. (2022). Triple negative breast cancer: Updates on classification and treatment in 2021. Cancers, 14(5), 1253. https://doi.org/10.3390/cancers14051253
  7. Brabec, V., & Kasparkova, J. (2005). Modifications of DNA by platinum complexes: Relation to resistance of tumors to platinum antitumor drugs. Drug Resistance Updates, 8(3), 131–146. https://doi.org/10.1016/j.drup.2005.04.006
  8. Clowse, M. E., & Wigley, F. M. (2003). Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. The Journal of Rheumatology, 30(6), 1341–1343. https://www.ncbi.nlm.nih.gov/pubmed/12784412
  9. Dai, C., Whitesell, L., Rogers, A. B., & Lindquist, S. (2007). Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell, 130(6), 1005–1018. https://doi.org/10.1016/j.cell.2007.07.020
  10. Desai, S., Liu, Z., Yao, J., Patel, N., Chen, J., Wu, Y., Ahn, E. E., Fodstad, O., & Tan, M. (2013). Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through transcriptional regulation of autophagy-related protein 7 (ATG7). Journal of Biological Chemistry, 288(13), 9165–9176. https://doi.org/10.1074/jbc.M112.422071
  11. Grunt, T. W., Somay, C., Pavelka, M., Ellinger, A., Dittrich, E., & Dittrich, C. (1991). The effects of dimethyl sulfoxide and retinoic acid on the cell growth and the phenotype of ovarian cancer cells. Journal of Cell Science, 100(3), 657–666. https://doi.org/10.1242/jcs.100.3.657
  12. Hashmi, A. A., Ajaz, Y., Sajjad, M., Zia, F., Irfan, M., Abu Bakar, S. M., Khan, E. Y., & Faridi, N. (2025). Predictive value of excision repair cross complementation group 1 (ERCC1) by immunohistochemistry for determining neoadjuvant chemotherapy response in triple-negative breast cancers. The Breast Journal, 2025, 8410670. https://doi.org/10.1155/tbj/8410670
  13. Hruban, R. H., Sternberg, S. S., Meyers, P., Fleisher, M., Menendez-Botet, C., & Boitnott, J. K. (1991). Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Investigation, 9(3), 263–268. https://doi.org/10.3109/07357909109021323
  14. Kawara, H., Akahori, R., Wakasugi, M., Sancar, A., & Matsunaga, T. (2019). DCAF7 is required for maintaining the cellular levels of ERCC1-XPF and nucleotide excision repair. Biochemical and Biophysical Research Communications, 519(1), 204–210. https://doi.org/10.1016/j.bbrc.2019.08.147
  15. Kovács, D., Sigmond, T., Hotzi, B., Bohar, B., Fazekas, D., Deak, V., Vellai, T., & Barna, J. (2019). HSF1Base: A comprehensive database of HSF1 (heat shock factor 1) target genes. International Journal of Molecular Sciences, 20(22), 5815. https://doi.org/10.3390/ijms20225815
  16. Lee, J. (2023). Current treatment landscape for early triple-negative breast cancer (TNBC). Journal of Clinical Medicine, 12(4), 1524. https://doi.org/10.3390/jcm12041524
  17. Li, Q., Yu, J. J., Mu, C., Yunmbam, M. K., Slavsky, D., Cross, C. L., BostickBruton, F., & Reed, E. (2000). Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Research, 20, 645–652.
  18. Lin, C., Cui, J., Peng, Z., Qian, K., Wu, R., Cheng, Y., & Yin, W. (2022). Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: Meta-analysis. European Journal of Medical Research, 27(1), 201. https://doi.org/10.1186/s40001-022-00839-0
  19. Ma, E. L. B., & El Kashef, W. F. (2017). ERCC1 expression in metastatic triple negative breast cancer patients treated with platinum-based chemotherapy. Asian Pacific Journal of Cancer Prevention, 18(2), 507–513. https://doi.org/10.22034/APJCP.2017.18.2.507
  20. Marteijn, J. A., Lans, H., Vermeulen, W., & Hoeijmakers, J. H. (2014). Understanding nucleotide excision repair and its roles in cancer and ageing. Nature Reviews Molecular Cell Biology, 15(7), 465–481. https://doi.org/10.1038/nrm3822
  21. Mendillo, M. L., Santagata, S., Koeva, M., Bell, G. W., Hu, R., Tamimi, R. M., Fraenkel, E., Ince, T. A., Whitesell, L., & Lindquist, S. (2012). HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell, 150(3), 549–562. https://doi.org/10.1016/j.cell.2012.06.031
  22. Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H. J., Hayashi, K., Groshen, S., Salonga, D., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Konda, B., & Leichman, L. (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. Journal of Clinical Oncology, 16(1), 309–316. https://doi.org/10.1200/JCO.1998.16.1.309
  23. Page, T. J., Sikder, D., Yang, L., Pluta, L., Wolfinger, R. D., Kodadek, T., & Thomas, R. S. (2006). Genome-wide analysis of human HSF1 signaling reveals a transcriptional program linked to cellular adaptation and survival. Molecular BioSystems, 2(12), 627–639. https://doi.org/10.1039/b606129j
  24. Pathak, N., Sharma, A., Elavarasi, A., Sankar, J., Deo, S. V. S., Sharma, D. N., Mathur, S., Kumar, S., Prasad, C. P., Kumar, A., & Batra, A. (2022). Moment of truth—Adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level meta-analysis. The Breast, 64, 7–18. https://doi.org/10.1016/j.breast.2022.04.006
  25. Powers, M. V., & Workman, P. (2007). Inhibitors of the heat shock response: Biology and pharmacology. FEBS Letters, 581(19), 3758–3769. https://doi.org/10.1016/j.febslet.2007.05.040
  26. Sidoni, A., Cartaginese, F., Colozza, M., Gori, S., & Crino, L. (2008). ERCC1 expression in triple negative breast carcinoma: The paradox revisited. Breast Cancer Research and Treatment, 111(3), 569–570. https://doi.org/10.1007/s10549-007-9804-4
  27. de Sousa, G. F., Wlodarczyk, S. R., & Monteiro, G. (2014). Carboplatin: Molecular mechanisms of action associated with chemoresistance. Brazilian Journal of Pharmaceutical Sciences, 50(4), 693–701. https://doi.org/10.1590/S1984-82502014000400004
  28. Tuncer, S., Gurbanov, R., Sheraj, I., Solel, E., Esenturk, O., & Banerjee, S. (2018). Low dose dimethyl sulfoxide driven gross molecular changes have the potential to interfere with various cellular processes. Scientific Reports, 8(1), 14828. https://doi.org/10.1038/s41598-018-33234-z
  29. Verheijen, M., Lienhard, M., Schrooders, Y., Clayton, O., Nudischer, R., Boerno, S., Timmermann, B., Selevsek, N., Schlapbach, R., Gmuender, H., Gotta, S., Geraedts, J., Herwig, R., Kleinjans, J., & Caiment, F. (2019). DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro. Scientific Reports, 9(1), 4641. https://doi.org/10.1038/s41598-019-40660-0
  30. Voorhees, P. M., Chen, Q., Kuhn, D. J., Small, G. W., Hunsucker, S. A., Strader, J. S., Corringham, R. E., Zaki, M. H., Nemeth, J. A., & Orlowski, R. Z. (2007). Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clinical Cancer Research, 13(21), 6469–6478. https://doi.org/10.1158/1078-0432.CCR-07-1293
  31. Vyas, D., Laput, G., & Vyas, A. K. (2014). Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis. OncoTargets and Therapy, 7, 1015–1023. https://doi.org/10.2147/OTT.S60114
  32. Wang, S., Zhang, H., Cheng, L., Evans, C., & Pan, C. X. (2010). Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. Anticancer Research, 30(11), 4573–4578. https://www.ncbi.nlm.nih.gov/pubmed/21115908
  33. Welsh, C., Day, R., McGurk, C., Masters, J. R., Wood, R. D., & Koberle, B. (2004). Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. International Journal of Cancer, 110(3), 352–361. https://doi.org/10.1002/ijc.20134
  34. Yun, C. W., Kim, H. J., Lim, J. H., & Lee, S. H. (2019). Heat shock proteins: Agents of cancer development and therapeutic targets in anti-cancer therapy. Cells, 9(1), 60. https://doi.org/10.3390/cells9010060